TY - CHAP M1 - Book, Section TI - Toxicity & Dose Modification of Chemotherapeutic Agents A1 - Wang, Sunny A1 - Dea, Tiffany O. A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. PY - 2023 T2 - Current Medical Diagnosis & Treatment 2023 AB - Key Clinical Updates in Toxicity & Dose Modification of Chemotherapeutic AgentsThe main toxicities of immune checkpoint inhibitors involve immune-related adverse events which occur via the same mechanisms as their antitumor effects (ie, self-reactive T-cells escaping central tolerance). The combination of PD-1 or PD-L1 inhibitors with CTLA-4 inhibitors results in higher rates of grade 3 or higher and all grades of immune-related adverse events.Brahmer JR et al. J Immunother Cancer. [PMID: 34172516] SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193162850 ER -